Eternity Biotech
Private Company
Funding information not available
Overview
Eternity Biotech is a private, pre-revenue biotech company pioneering a novel approach to life extension and anti-aging based on genetic targets pch-2 and bmk-1. Founded in 2016, the company has demonstrated proof-of-concept in C. elegans, showing a 25% lifespan extension, and has begun translating this work into human cell models. Led by a founder with a venture capital background and a CSO with drug development experience, the company is currently raising capital via a WeFund campaign to advance its research toward therapeutic development.
Technology Platform
A gene-centric platform targeting pch-2 and bmk-1 (human analog KIF11) pathways, discovered in C. elegans, to extend lifespan and enhance cellular stress resilience. The platform involves validating these targets in human cell models for therapeutic development.
Opportunities
Risk Factors
Competitive Landscape
The longevity biotech field is becoming increasingly crowded with well-funded startups (e.g., Unity Biotechnology, Calico Life Sciences, Altos Labs) and large pharma interest. Competition is intense for talent, funding, and intellectual property. Eternity's niche focus on specific genetic targets (pch-2/bmk-1) differentiates it, but it is a very early and small player.